Yes, pure and simple, it failed in the OA animal model. I'm not even sure why they tested it in OA. What was the company's rationale for testing platelet-derived exosomes in OA? The company needs to show sections of the animal joint at Day 0 and include invitro studies to justify their reasoning, even though regulatory agencies won't even look at their drug if it doesn't heal more severe cases of OA.
In regards to PLEX II, there is insufficient evidence to suggest it doesn't work. That is because the wounds healed in both the control and treatment groups, so it could still work, but they need to test it in an appropriate group where wound healing is a challenge, for example in patients with diabetes. I would like to see EX1 test it in diabetic patients, but i'm not sure if they've done the requisite animal work for example testing their treatment in db/db mice.
100% agree with your blind optimist statement as well.
- Forums
- ASX - By Stock
- TYP
- Ann: Preclinical Data from Osteoarthritis Animal Study
Ann: Preclinical Data from Osteoarthritis Animal Study, page-42
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TYP (ASX) to my watchlist
|
|||||
Last
2.2¢ |
Change
0.002(10.0%) |
Mkt cap ! $23.95M |
Open | High | Low | Value | Volume |
1.9¢ | 2.2¢ | 1.9¢ | $45.08K | 2.206M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 609812 | 2.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.2¢ | 1132693 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 609812 | 0.020 |
3 | 2400000 | 0.019 |
4 | 532509 | 0.018 |
2 | 775000 | 0.017 |
2 | 978231 | 0.016 |
Price($) | Vol. | No. |
---|---|---|
0.022 | 1132693 | 3 |
0.023 | 750000 | 2 |
0.024 | 290529 | 2 |
0.025 | 715614 | 3 |
0.027 | 300000 | 1 |
Last trade - 15.13pm 19/08/2024 (20 minute delay) ? |
Featured News
TYP (ASX) Chart |